• English
  • 简体中文
Login Register
Current Location: Home > Marketing Drugs(EU) Feedback Help
EMA Approvals
-
HMA Approvals
-

EMA:Drugs approved by European Medicines Agency through centralized Procedure. 

HMA:Drugs approved by EU members through Mutual Recognition Procedure.

For more information check in official website of members:

Drug label information in UK

Public Assessment Reports in UK

Marketed drugs in France

Marketed drugs in Italy

Marketed drugs in Switzerland

Marketed drugs in Sweden

Marketed drugs in Germany

Click here for more information

Brand name Nonproprietary Name Authorization date Marketing authorisation holder
Posaconazole Accord posaconazole 2019-07-26 Accord Healthcare S.L.U.
Rivastigmine Actavis rivastigmine 2011-06-17 Actavis Group PTC ehf
Maviret glecaprevir, pibrentasvir 2017-07-27 AbbVie Deutschland GmbH Co. KG
Poteligeo mogamulizumab 2018-11-23 Kyowa Kirin Holdings B.V.
VeraSeal human fibrinogen, human thrombin 2017-11-11 Instituto Grifols, S.A.
Retacrit epoetin zeta 2007-12-19 Pfizer Europe MA EEIG
Bronchitol mannitol 2012-04-14 Pharmaxis Europe Limited
Soliris eculizumab 2007-06-21 Alexion Europe SAS
Tevagrastim filgrastim 2008-09-16 Teva GmbH
Karvezide irbesartan, hydrochlorothiazide 1998-10-17 Sanofi-aventis groupe
Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron) dinutuximab beta 2017-05-09 EUSA Pharma (Netherlands) BV
Odomzo sonidegib 2015-08-15 Sun Pharmaceutical Industries Europe B.V.
Epidyolex cannabidiol 2019-09-20 GW Pharma (International) B.V.
Braftovi encorafenib 2018-09-20 Pierre Fabre Medicament
Alymsys bevacizumab 2021-03-27 Mabxience Research SL
Galafold migalastat 2016-05-26 Amicus Therapeutics Europe Limited
Sivextro tedizolid phosphate 2015-03-24 Merck Sharp & Dohme B.V.
Fabrazyme agalsidase beta 2001-08-04 Genzyme Europe BV
Lixiana edoxaban 2015-06-20 Daiichi Sankyo Europe GmbH
Retsevmo selpercatinib 2021-02-12 Eli Lilly Nederland B.V.